Pharmacist-led Chemotherapy Counseling: Impact on Hospital Admissions, Patient Satisfaction, and Cost Avoidance – A Prospective Pre–post Quality Improvement Study

ABSTRACT

Objective:

This study evaluated the impact of structured clinical pharmacist-led counseling on hospital admissions due to chemotherapy side effects, patient satisfaction, and cost avoidance in patients receiving intravenous chemotherapy.

Methods:

A prospective pre–post quality improvement study was conducted at a tertiary care center in Saudi Arabia. The preintervention cohort (October 2024–February 2025, n = 118) received standard care; the postintervention cohort (April–August 2025, n = 135) received structured 30-min pharmacist-led counseling covering regimen-specific education, anticipatory guidance on toxicity, self-management strategies, red-flag symptom recognition, and monitoring protocols. The primary outcome was the hospital admission rate due to chemotherapy-related side effects. Secondary outcomes included side effect-specific admissions, patient satisfaction, and economic impact.

Findings:

The intervention achieved a 34.4% relative reduction in admission rates (13.56%–8.89%; P = 0.02; number needed to treat = 22). Complete elimination of admissions for gastrointestinal toxicities and 38.8% reduction in febrile neutropenia admissions were observed. Patient satisfaction reached 94.4%, with 97.2% service coverage. Net cost savings totaled $38,850 over 5 months (ROI: 747%), with febrile neutropenia prevention accounting for 76.6% of savings.

Conclusion:

Structured pharmacist-led counseling significantly reduced chemotherapy-related hospital admissions, achieved exceptional patient satisfaction, and demonstrated strong economic value, supporting its integration as standard supportive care in oncology practice.

INTRODUCTION

Systemic anticancer therapy is increasingly delivered in ambulatory and outpatient contexts, shifting substantial responsibility for day-to-day monitoring and management of treatment-related toxicities to patients and caregivers between scheduled oncology visits.[1,2] Treatment-related adverse effects remain clinically consequential; contemporary chemotherapy care protocols consistently emphasize that toxicities can be distressing and potentially life-threatening and may precipitate acute care utilization (emergency department visits and hospitalizations) when not detected early or managed appropriately.[1,2] The economic implications of cancer care and of interventions intended to mitigate complications are longstanding and salient, with oncology literature explicitly highlighting the relevance of costs in treatment decisions and health system sustainability.[3,4] These trends motivate rigorous evaluation of supportive care strategies that can improve toxicity management, reduce avoidable hospital use, and enhance patient experience while remaining economically justifiable.[1,4]

Clinical pharmacist-led counseling constitutes a plausible, scalable supportive care approach because it targets modifiable drivers of toxicity-related harm: medication knowledge gaps, suboptimal self-management, delayed reporting of symptoms, and drug-related problems arising from complex regimens.[5,6] Within oncology specifically, systematic reviews have synthesized evidence that clinical pharmacy services in oncology/hematology centers can improve care processes and patient outcomes (identification/resolution of drug-related problems, optimization of therapy, and patient education/counseling), with some studies also reporting economic benefits.[5,6] However, the heterogeneity of oncology populations, chemotherapy modalities, and intervention components, particularly the variability in the intensity and content of counseling focused on side-effect recognition and management, limits direct inference about the impact of pharmacist-led counseling on hard endpoints such as hospital admissions and total costs.[5,6]

Chemotherapy toxicity management is a priority because adverse effects are frequently predictable and therefore potentially preventable through anticipatory guidance, early detection, and timely supportive interventions between scheduled visits.[1,2] Pragmatic trial protocols developed in response to real-world care gaps explicitly note that emergency department visits and hospitalizations during chemotherapy occur commonly in routine practice and may exceed rates observed in clinical trials, reinforcing the importance of service models that provide “between-visit” support.[2] Evidence from systematic reviews demonstrates that pharmacist-led interventions can improve symptom control and reduce chemotherapy-induced complications. A recent meta-analysis demonstrated that clinical pharmacy services significantly reduce chemotherapy-induced nausea and vomiting, with odds ratios (ORs) of 1.92 for nausea (P = 0.003) and 2.49 for vomiting (P = 0.014).[7] Multiple randomized controlled trials have corroborated these findings, reporting significant reductions in fatigue, nausea/vomiting, pain, and gastrointestinal (GI) symptoms following pharmacist interventions.[8,9] Specialized symptom management programs have achieved substantial reductions in symptom severity through pharmacist-led collaborative drug therapy management.[10] Quality of life improvements represent one of the most consistently reported benefits. Randomized controlled trials have demonstrated statistically significant reductions in anxiety and depression using validated instruments, with improvements in overall quality of life scores.[11,12] Medication adherence improvements have been substantial, with studies reporting adherence improvements from 86% to 94.7% alongside dramatic knowledge improvements.[13]

Economic benefits are well-documented across multiple studies. Research has reported significant reductions in emergency department visits (from 3.34% to 1.72%) and inpatient admissions (from 2.43% to 0.34%), with corresponding cost savings of approximately $204,437.[14] Other studies have achieved statistically significant reductions in unplanned healthcare use through comprehensive management programs incorporating pharmacist involvement.[15] Cost-effectiveness analyses have reported acceptable incremental cost-effectiveness ratios, supporting the economic viability of pharmacist counseling programs.[16] A systematic review encompassing 4771 patients reported consistent findings of reduced hospital stays and cost reductions across multiple oncology settings.[5]

Patient satisfaction outcomes have been consistently positive, with studies reporting statistically significant increases in satisfaction scores alongside reductions in drug-related problems.[17] In oncology-relevant randomized evidence, intensified pharmaceutical care has been evaluated not only for medication safety but also for patient-reported outcomes and treatment perception.[18]

Despite accumulating evidence that clinical pharmacy services in oncology can improve medication safety, supportive care processes, and selected patient outcomes, there remains a specific evidence gap regarding clinical pharmacist-led counseling for patients receiving chemotherapy, focused explicitly on chemotherapy side effects, evaluated against hospital admissions, patient satisfaction, and cost within a single coherent study framework.[5,6] Existing oncology pharmacy evidence frequently focuses on single-toxicity domains (e.g., nausea and vomiting) or oral anticancer agents.[7,18] Moreover, the field continues to emphasize the need for higher-quality, comparable economic evaluation methods for pharmaceutical care, particularly when complex interventions are implemented in real-world hospital systems.[19]

Accordingly, the present study was designed to evaluate the impact of clinical pharmacist-led counseling for patients receiving chemotherapy regarding chemotherapy side effects on (i) hospital admissions, (ii) patient satisfaction, and (iii) cost, addressing an applied gap at the intersection of toxicity management, patient-centered care, and health-system value in contemporary oncology practice.

METHODS

Study design and setting

This prospective quality improvement project employed a pre–post comparative design to evaluate the impact of structured pharmacist-led counseling on chemotherapy-related outcomes. The study was conducted at the Armed Forces Hospital Southern Region (AFHSR), a tertiary care center providing comprehensive oncology services in Saudi Arabia. The pre-intervention (baseline) cohort was retrospectively identified from October 2024 through February 2025, and the postintervention cohort was prospectively enrolled from April through August 2025. March 2025 served as an implementation period during which pharmacist training and workflow implementation occurred.

Before the intervention, no structured patient counseling program existed at AFHSR. Patients received only ad hoc verbal information from oncologists or nursing staff during routine clinical encounters, with no dedicated counseling session, standardized content, or written materials.

Study population

Inclusion criteria

Adult patients (≥18 years) receiving intravenous or inpatient chemotherapy at AFHSR during the study periods were eligible for inclusion. Both newly initiated and ongoing chemotherapy regimens were included in the study.

Exclusion criteria

Patients receiving exclusively oral anticancer therapy in the outpatient setting without inpatient or infusion center visits were excluded, as were those who declined to participate in counseling or satisfaction surveys.

Intervention

Pharmacist training and preparation

During March 2025, clinical and oncology pharmacists underwent structured training on chemotherapy protocols, toxicity profiles, patient education strategies, and communication techniques. Training materials were developed based on the latest available 2025 versions of evidence-based guidelines from the British Columbia Cancer Agency, Cancer Care Ontario, and the National Comprehensive Cancer Network. Standardized patient education materials covering common chemotherapy regimens and their associated toxicities were prepared in both English and Arabic.

Counseling intervention components

The pharmacist-led counseling intervention consisted of structured, individualized sessions delivered before the first or second chemotherapy cycle, with additional reinforcement during subsequent cycles as clinically indicated. Each counseling session, lasting approximately 30 min, included five core components:

1. Regimen-specific education: Detailed explanation of the chemotherapy regimen, mechanism of action, treatment schedule, and expected duration

2. Toxicity anticipatory guidance: Discussion of common and serious side effects specific to the prescribed regimen, including timeline of onset and expected duration

3. Self-management strategies: Practical instruction on symptom prevention and management, including hydration protocols, antiemetic optimization, neutropenia precautions, dietary modifications, and supportive care measures

4. Red-flag symptom recognition and escalation guidance: Clear criteria for when to contact the healthcare team or seek emergency care, with emphasis on fever, dehydration, bleeding, and severe GI symptoms

5. Protocol-specific monitoring: Education on required laboratory monitoring (e.g., renal function for cisplatin-based regimens, complete blood counts for myelosuppressive agents) and the rationale for surveillance.

Patients received written educational materials summarizing key counseling points, emergency contact information, and symptom management algorithms.

Workflow Integration: Workflow redesign included allocating protected pharmacist time for counseling activities, integrating counseling documentation into the electronic health record, and establishing a tracking system to ensure all eligible patients were offered counseling. Pharmacists documented counseling content, patient comprehension, and any identified concerns or barriers in standardized templates.

Outcome measures

Primary outcome

The primary outcome was the hospital admission rate due to chemotherapy-related side effects, defined as the proportion of patients in each cohort requiring unplanned inpatient admission for management of treatment-related toxicities. Admissions were identified through review of electronic medical records, and causality was independently assessed by two clinical pharmacists using documented admission diagnoses and clinical narratives.

Secondary outcomes: Secondary outcomes are as follows:

Clinical outcomes:

• Incidence of specific chemotherapy-related toxicities (febrile neutropenia, GI toxicities including diarrhea and vomiting, constitutional symptoms)

• Side effect-specific admission rates

• Regimen-specific admission patterns.

Process and implementation outcomes:

• Coverage rate: proportion of eligible patients who received pharmacist-led counseling

• Barriers to counseling delivery.

Patient-reported outcomes:

• Overall satisfaction with counseling service

• Perceived benefit of counseling

• Confidence in self-management of side effects

• Barriers to accessing counselling.

Economic outcomes:

• Estimated cost avoidance from prevented hospital admissions

• Cost per patient counseled

• Return on investment (ROI).

Data collection

Preintervention cohort

Data for the baseline cohort were retrospectively extracted from electronic health records, including patient demographics, cancer diagnoses, chemotherapy regimens, documented toxicities, and hospital admissions with associated diagnoses and dates. Only admissions clearly attributable to chemotherapy toxicities were included in the study.

Postintervention cohort

Data for the intervention cohort were prospectively collected, including all baseline variables, counseling documentation (date, duration, content, and materials provided), and real-time tracking of toxicities and admissions.

Patient satisfaction survey

A standardized satisfaction questionnaire was administered to patients in the intervention cohort who received counseling, either at a follow-up visit or by telephone, within 4 weeks of counseling. The survey assessed overall satisfaction (5-point Likert scale), timing of counseling delivery, perceived benefits, confidence in managing side effects, and barriers to accessing services. The survey was available in English and Arabic.

Cost estimation methodology

Healthcare costs associated with prevented admissions were estimated using published episode costs from peer-reviewed literature, adjusted for the Saudi healthcare context using World Health Organization purchasing power parity indices. Base cost estimates per admission episode were:

• Febrile neutropenia: US dollars (USD) $7,500 (derived from Flanigan et al.,[20] who reported mean US costs of $25,176, adjusted to approximately 30% to reflect Saudi healthcare system costs based on the WHO purchasing power parity indices)

• Severe GI complications (diarrhea with hypotension) requiring intravenous fluids and monitoring: USD $6,500[21]

• Moderate GI complications (diarrhea, vomiting): USD $3,000–$5,000 (based on Dulisse et al.[21] and regional cost adjustments)

• Febrile episodes without neutropenia: USD $6,000 (based on Saxena et al.[22])

• Minor complications (e.g., hiccup): USD $3,000 (based on Schelenz et al.[23]).

All costs are presented in USD. Exchange rate: 1 USD = 3.75 SAR (fixed rate).

Expected admissions in the intervention cohort (absent counseling) were calculated by applying pre-intervention admission rates to the postintervention cohort size. Cost avoidance was calculated as: (expected admissions − actual admissions) × cost per episode. Program costs included pharmacist time (30 min per patient at USD $40/h), one-time training costs (USD $2,000), and educational materials (USD $500). Net cost savings were calculated by subtracting total program costs from gross cost avoidance. ROI was calculated as: (net savings ÷ program costs) ×100.

Statistical analysis and sample size calculation

Descriptive statistics were calculated for patient demographics, chemotherapy regimens, and outcomes in both cohorts. Categorical variables were reported as frequencies and percentages; continuous variables as means with standard deviations or medians with interquartile ranges, as appropriate. The primary outcome (admission rate) was compared between cohorts using the Chi-square test for proportions. Absolute risk reduction, relative risk reduction, and number needed to treat (NNT) with 95% confidence intervals were calculated. Secondary outcomes were similarly analyzed using Chi-square or Fisher’s exact tests for categorical variables. Subgroup analyses were performed by chemotherapy regimen and cancer type to identify differential effects of the intervention. Statistical significance was defined as P < 0.05 (two-tailed). All analyses were conducted using SPSS version 28 (IBM Corp., Armonk, N.Y., USA).

This was a quality improvement project using consecutive convenience sampling of all eligible patients receiving intravenous chemotherapy during the preintervention (October 2024–February 2025) and post-intervention (April 2025–August 2025) periods. No formal a priori sample size calculation was conducted, as the study was designed to evaluate a service-wide intervention rather than test a pre-specified hypothesis. The satisfaction survey was offered to all postintervention patients as a census of service users rather than a sample; no a priori sample size calculation was performed. The achieved response (79%) provides 95% confidence interval precision of approximately ± 10% or better for descriptive satisfaction proportions.

Ethical considerations

The project was reviewed and approved by the AFHSR Quality Improvement Committee as a quality improvement initiative (QIP: 123/2025). As this was a service improvement project evaluating standard-of-care interventions, formal institutional review board approval was not required per institutional policy. Verbal informed consent was obtained from all patients who received counselling to utilize their anonymized data for research purposes. All patient data were anonymized before analysis. Counseling was offered to all eligible patients as part of routine care; participation in satisfaction surveys was voluntary. The project adhered to institutional guidelines for quality improvement, patient confidentiality, and data protection.

RESULTS

The preintervention cohort (October 2024–February 2025) consisted of 118 patients, while the postintervention cohort (April 2025–August 2025) comprised 135 patients who received chemotherapy. Figure 1 presents the selection and flow of patients through the study.

Figure 1.

Selection and flow of patients through the study

Primary and secondary outcomes

Primary outcome

The intervention achieved a 34.4 % relative reduction in admission rates (P = 0.028) in the post-intervention cohort, preventing approximately one hospitalization for every 22 patients counseled (NNT = 22) [Figure 2].

Figure 2.

Hospital admission rates

Pre-intervention Period: October 2024 - February 2025

• Total patients: 118

• Hospital admissions: 16 (13.56 %)

Post-intervention Period: April 2025 - August 2025

• Total patients: 135

• Hospital admissions: 12 (8.89 %)

• - Based on the pre-intervention admission rate, expected admissions without intervention:

• 135 × 13.56 % = 18.3 admissions

• - Actual admissions with intervention: 12 admissions

• - Admissions prevented: 18.3 – 12 = 6.3

Secondary outcomes

Side effect analysis

Table 1 presents the most successfully reduced substantial reductions in side effects following the intervention.

Table 1.

Most successfully reduced side effects

Side effect	Preintervention	Preintervention rate (%)	Expected admissions without intervention*	Postintervention	Postintervention rate (%)	Admissions prevented	Reduction
Eliminated side effects admissions
Diarrhea with hypotension	2	1.7	2.3	0	0.0	2.3	100%
Diarrhea	1	0.8	1.1	0	0.0	1.1	100%
Vomiting	1	0.8	1.1	0	0.0	1.1	100%
Hiccup	1	0.8	1.1	0	0.0	1.1	100%
Fever with acute tonsillitis	1	0.8	1.1	0	0.0	1.1	100%
Reduced side effects admissions
Febrile neutropenia	10	8.5	11.5	7	5.2	4.5	38.8%
New side effects postintervention admissions
Neutropenia with other symptoms	0	0.0	0	3	2.2	−3	New
Hypersensitivity reaction	0	0.0	0	1	0.7	−1	New
Fever (nonneutropenic)	0	0.0	0	1	0.7	−1	New
Total admissions	16	13.56	18.3	12	8.89	6.3	34.4%

*Expected admissions calculated by applying preintervention rates to the postintervention cohort of 135 patients. Values represent admission counts and rates per cohort. Expected admissions calculated by applying preintervention rates to the postintervention cohort (n=135). Reduction=(Expected−Actual)/Expected×100%. The sum of individual prevented admissions (11.3) exceeds the total prevented admissions (6.3) because the postintervention period also saw 5 new admissions for conditions not seen preintervention (3 cases of neutropenia with other symptoms, 1 hypersensitivity reaction, 1 nonneutropenic fever)

Emerging patterns post-intervention

• Neutropenia (with other symptoms): 0 → 3 cases (new category)

• Hypersensitivity Reaction: 0 → 1 case

• Fever (non-neutropenic): 0 → 1 case.

Figures 3 and 4 represent side effect-specific admissions and side effect reduction rates, respectively.

Figure 3.

Side effect-specific admissions

Figure 4.

Side effect reduction rates

Chemotherapy regimen analysis

Regimens with a reduction in hospital admissions from preintervention to postintervention:

1. TC (Docetaxel/Cyclophosphamide): 3 → 0 admissions (100% reduction)

2. TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab): 3 → 1 admissions (66.7% reduction)

3. AC (Doxorubicin, Cyclophosphamide) second line: 1 → 0 admissions (100% reduction)

4. Irinotecan: 1 → 0 admissions (100% reduction)

5. FOLFOX/panitumumab: 1 → 0 admissions (100% reduction).

Regimen-specific side effects and their reduction from pre-intervention to post-intervention:

TCPH regimen (most common preintervention):

• Pre: Diarrhea (1), Febrile Neutropenia (2)

• Post: Febrile Neutropenia (1)

• Improvement: 66.7% reduction in side effects.

TC regimen:

• Pre: Febrile neutropenia (3)

• Post: None

• Improvement: 100% reduction.

Figure 5 illustrates the subgroup analysis by cancer type and chemotherapy regimen.

Figure 5.

Subgroup analysis by cancer type and chemotherapy regimen

Clinical patterns

1. Febrile neutropenia management: The intervention reduced febrile neutropenia-related admissions from an expected 11.5–7 actual admissions (38.8% reduction), the most common cause of admission

2. GI side effect prevention: Complete elimination of admissions for isolated GI side effects (diarrhea, vomiting, hiccups), preventing an estimated 3.3 admissions

3. TC/TCPH regimens: These commonly used regimens showed excellent response to counseling intervention

4. Trade-off considerations: While preventing many traditional side effects, five new admission types emerged postintervention, suggesting improved detection/reporting of complex presentations rather than intervention failure.

Patient satisfaction with the intervention (counselling service)

One hundred and seven out of 135 participants (response rate: 79%) completed the satisfaction questionnaire. Among those who responded, 60% were females. Other demographics are presented in Table 2.

Table 2.

Patient demographics

Characteristic	n (%)
Gender
Female	64 (59.8)
Male	43 (40.2)
Age groups (years)
18–29	8 (7.5)
30–49	29 (27.1)
50–69	55 (51.4)
70+	15 (14.0)
Top cancer types
Breast cancer	30 (28.0)
Colon cancer	25 (23.4)
Other cancers	52 (48.6)

Descriptive statistics only; categorical variables presented as frequencies and percentages (n=107 survey respondents)

A satisfaction level of 94.4% was achieved with the overall counselling service, which is exceptional by healthcare standards. The following figures present the detailed results of the satisfaction questionnaire.

Economic evaluation of the intervention (counseling service)

Cost savings analysis

Table 3 presents cost savings per chemotherapy side effect.

Table 3.

Actual cost savings by chemotherapy side effect (5-month period)

Side effect	Expected admissions	Actual admissions	Admissions prevented	Cost per episode (USD)	Total cost savings (USD)
Febrile neutropenia	11.5	7	4.5	$750020	$33,750
Diarrhea with hypotension	2.3	0	2.3	$650021	$14,950
Fever with acute tonsillitis	1.1	0	1.1	$600022	$6600
Diarrhea	1.1	0	1.1	$500021	$5500
Vomiting	1.1	0	1.1	$450021	$4950
Hiccup	1.1	0	1.1	$300023	$3300
New complications*	0	5	−5	$5000**	−$25,000
Total	18.3	12	6.3	-	$44,050

*New complications include: Neutropenia with other symptoms (3), hypersensitivity reaction (1), nonneutropenic fever (1), **Average cost estimated for new complications. Deterministic cost estimates calculated as (Expected−Actual admissions) × cost per episode; episode costs obtained from published literature and adjusted for the Saudi context using the WHO purchasing power parity indices. WHO=World Health Organization

Key economic indicators

Cost-effectiveness metrics:

• Total gross savings from prevented admissions: $69,050 (prevented traditional side effects)

• Cost of new admissions: $25,000 (5 new complications)

• Net cost savings: $44,050

• Cost savings per patient: $326

• Cost savings per admission prevented: $6,992.

Program investment (estimated):

• Pharmacist time: 30 min per patient × 135 patients = 67.5 h

• Hourly pharmacist cost: $40/h (regional estimate)

• Total pharmacist time cost: $2,700

• Training costs (one-time): $2,000

• Educational materials: $500

• Total program cost: $5,200.

ROI:

• Net savings after program costs: $44,050–$5,200= $38,850

• ROI: ($38,850/$5,200) × 100 = 747%

• For every $1 invested, the program saved $7.47.

Economic impact summary

Pharmacist-led counseling intervention remains highly cost-effective despite more conservative calculations:

• Primary finding: Net cost savings of $38,850 over 5 months after accounting for program costs

• Cost per quality-adjusted outcome: With an NNT of 22 and program cost of $5,200, the cost per admission prevented is approximately $237, well below the $6,992 value of each prevented admission

• Sustainability: The 747% ROI strongly supports continued funding and potential expansion.

• Most impactful prevention: Febrile neutropenia prevention accounts for 76.6% of gross savings, highlighting the importance of neutropenia education.

DISCUSSION

This quality improvement project demonstrated that structured, clinical pharmacist-led counseling for patients receiving chemotherapy resulted in a statistically significant 34.4% relative reduction in hospital admissions due to treatment-related side effects (13.56% to 8.89%; P = 0.028; NNT = 22). The intervention achieved complete elimination of admissions for isolated GI toxicities (diarrhea, vomiting, hiccups) and a 38.8% reduction in febrile neutropenia-related admissions. With 97.2% service coverage, 94.4% patient satisfaction, and a ROI of 747% (net savings of $38,850 over 5 months), the intervention proved clinically effective, highly acceptable, and economically favorable. Regimen-specific analyses revealed differential responses, with TC and AC second-line regimens achieving 100% admission reduction, while TCPH showed 66.7% reduction, underscoring the value of targeted, protocol-specific counseling.

Clinical effectiveness: Hospital admissions and toxicity management

Our 34.4% reduction in chemotherapy-related hospital admissions aligns with, though is more conservative than, findings from Mull et al.,[14] who reported reductions in emergency department visits from 3.34% to 1.72% and inpatient admissions from 2.43% to 0.34% following oncology pharmacist integration. The more modest effect size in our study likely reflects differences in patient populations, intervention intensity, and baseline admission rates. Notably, our baseline admission rate of 13.56% substantially exceeds rates reported in controlled trials, supporting the pragmatic trial literature’s assertion that real-world toxicity-related acute care utilization often surpasses clinical trial benchmarks,[2] thereby creating greater opportunity for preventive interventions.

The complete elimination of admissions for isolated GI toxicities represents a particularly striking finding that extends beyond existing literature. While Shin et al.’s meta-analysis[7] demonstrated that pharmacy services significantly reduce chemotherapy-induced nausea and vomiting (OR 1.92 for nausea, OR 2.49 for vomiting), and individual trials by Alkashaf and Mohammed[8] and Wang et al.[9] reported significant symptom reductions, but none documented complete elimination of GI-related hospitalizations. This suggests that structured anticipatory guidance on hydration protocols, antiemetic optimization, and early self-management may be especially effective for preventing escalation of predictable, manageable toxicities. The mechanistic plausibility is strong: GI symptoms, unlike infectious complications, are largely amenable to patient-initiated interventions when patients possess adequate knowledge and confidence.

The 38.8% reduction in febrile neutropenia admissions (from 8.5% to 5.2%), whereas clinically meaningful, was less dramatic than that of GI toxicity prevention. This differential effectiveness is instructive and consistent with the pathophysiology of these complications. Febrile neutropenia, being an infectious/immunologic complication, is less directly modifiable through patient education alone compared to symptom-based toxicities. Nevertheless, the observed reduction likely reflects improved patient recognition of fever as a red-flag symptom, enhanced adherence to neutropenia precautions (hand hygiene, avoiding crowds, dietary restrictions), and earlier presentation before clinical deterioration necessitates admission. Homan et al. achieved a 69.2% reduction in symptom severity through collaborative drug therapy management, suggesting that more intensive pharmacist involvement, potentially including prescriptive authority for supportive medications, might further reduce neutropenia-related admissions.[10]

Regimen-specific outcomes: Tailoring interventions

The regimen-specific analysis revealed important heterogeneity in intervention effectiveness. The 100% elimination of admissions for TC (docetaxel/cyclophosphamide) and AC second-line regimens, compared to 66.7% reduction for TCPH, suggests that counseling effectiveness varies with regimen complexity and toxicity profile. TC regimens, whereas associated with significant neutropenia risk, have relatively predictable toxicity patterns that may be more amenable to standardized patient education. In contrast, TCPH (docetaxel/cyclophosphamide/trastuzumab/pertuzumab) involves greater pharmacologic complexity, longer infusion times, and potential for cardiac and hypersensitivity reactions that may be less preventable through patient self-management alone.

This finding has important implications for resource allocation and intervention design. It suggests that a risk-stratified approach, allocating more intensive pharmacist follow-up (e.g., telephone check-ins at days 3 and 7 post-chemotherapy) for complex regimens, may optimize efficiency while maintaining effectiveness. The existing literature has generally reported aggregate outcomes without regimen-specific stratification,[5,6] representing a gap that our findings begin to address.

Patient-centered outcomes: Satisfaction and empowerment

The 94.4% overall satisfaction rate substantially exceeds benchmarks in the pharmaceutical care literature and aligns with findings from Bollen et al., who reported statistically significant satisfaction increases following pharmacist medication reconciliation services.[17] The high satisfaction likely reflects multiple dimensions: the comprehensive nature of counseling (covering not only medication management but also practical self-care strategies), the dedicated time allocated for patient questions, and the provision of written materials for reference. Importantly, 88.8% of patients reported tangible benefits from counseling, and 97.2% received counseling before chemotherapy initiation, indicating both perceived value and successful implementation fidelity.

These findings complement the quality-of-life literature from randomized trials. Periasamy et al.[11] demonstrated significant reductions in anxiety and depression following pharmacist counseling, whereas Fujii et al.[12] reported EQ-5D-5L improvements from 0.82 to 0.86 (P < 0.01). Although we did not employ validated quality-of-life instruments, the high satisfaction and reported confidence in self-management suggest similar psychological benefits. The mechanism likely involves reduced uncertainty, enhanced self-efficacy, and perception of supported care, which are the factors known to influence patient experience in oncology.[11]

Economic value: Cost-effectiveness and sustainability

The economic analysis revealed net cost savings of $38,850 over 5 months (ROI 747%), with febrile neutropenia prevention accounting for 76.6% of gross savings. These findings align with the broader pharmacoeconomic literature demonstrating favorable cost-benefit ratios for pharmaceutical care interventions. Tanaka et al.[16] reported acceptable incremental cost-effectiveness ratios of 1.3–1.36 million yen per quality-adjusted life year for pharmacist counseling in breast cancer chemotherapy, whereas the systematic review by Oliveira et al.[5] encompassing 4771 patients, documented consistent cost reductions across oncology settings.

Our cost per-dmission prevented of $6992 compares favorably with published episode costs for chemotherapy complications. Flanigan et al.[20] reported mean US costs of $25,176 for febrile neutropenia episodes, whereas Dulisse et al.[21] documented substantial economic burden during hospitalizations for febrile neutropenia. Even after adjusting for Saudi healthcare system costs (approximately 30% of US costs based on the WHO purchasing power parity), the prevented admissions represent substantial value. The emergence of five new admission types postintervention (neutropenia with other symptoms, hypersensitivity reactions, nonneutropenic fever) warrants consideration but likely reflects improved detection and reporting rather than intervention induced harm.

Added value of this study

While previous studies have examined pharmacist-led interventions in oncology, including medication reconciliation, chemotherapy verification, and adherence counseling, most have focused on a single outcome (such as medication errors, adherence, or symptom management) and have been conducted predominantly in Western healthcare settings. The present study adds to the existing literature in several ways. First, it evaluates a structured pharmacist-led counseling service against a defined preintervention baseline within the same institution, allowing direct comparison of admission rates under routine and enhanced care. Second, it simultaneously assesses three outcomes that are less widely reported together (chemotherapy-related hospital admissions, patient satisfaction, and cost avoidance), providing a more comprehensive picture of clinical, patient-reported, and economic value. Third, it contributes data from a Middle Eastern tertiary cancer center, a setting that remains underrepresented in the published oncology pharmacy literature, and applies a locally adjusted cost framework using purchasing power parity to enhance the relevance of economic estimates to similar healthcare systems. Finally, the study demonstrates that such a service can be feasibly implemented within an existing oncology workflow using available pharmacy staff, offering a practical model that other resource-comparable institutions may adapt.

Limitations

Several limitations merit acknowledgment. First, the pre–post design without concurrent controls limits causal inference; temporal trends, seasonal variations, or concurrent quality initiatives may have contributed to observed improvements. Second, the relatively short intervention period (5 months) precludes assessment of long-term sustainability and seasonal variation in admission patterns. Third, single-center implementation at a tertiary military hospital may limit generalizability to community oncology settings or different healthcare systems with varying resources and patient populations. Fourth, the 79% satisfaction survey response rate, while acceptable, introduces potential response bias. Fifth, we did not employ validated quality-of-life or distress instruments, limiting our understanding of broader patient-centered impacts beyond satisfaction. Sixth, the economic analysis relied on published cost estimates adjusted for local context rather than actual institutional costs, introducing uncertainty in precise cost–benefit calculations. Finally, causality assessment for admissions was performed by clinical pharmacists rather than blinded adjudicators, potentially introducing classification bias.

Implications for practice and research

These findings support formalizing pharmacist-led chemotherapy counseling as a standard-of-care quality metric, with documentation of regimen-specific education before first-cycle administration serving as a measurable indicator. The intervention’s high ROI and patient acceptability justify resource allocation and provide a business case for sustained implementation. The regimen-specific variance observed suggests value in risk-stratified models that allocate enhanced follow-up (e.g., telephone toxicity checks) for complex regimens while maintaining baseline counseling for all patients. Integration with electronic health record prompts and antimicrobial stewardship programs may amplify benefits.

Future research should employ randomized or stepped-wedge designs across diverse sites to strengthen causal inference and assess scalability. Incorporation of validated patient-reported outcome measures (e.g., EORTC QLQ-C30, FACT-G, distress thermometer) would provide a richer assessment of patient-centered benefits. Comprehensive micro-costing studies using actual institutional data would refine economic evaluations. Finally, exploration of digital augmentation (SMS-based symptom monitoring, chatbot triage for toxicity queries) may enhance accessibility and enable real-time intervention while optimizing pharmacist time allocation.

CONCLUSION

In this single-center quality improvement project, implementation of a structured clinical pharmacist-led counseling service for patients receiving chemotherapy was feasible within the routine oncology workflow and was associated with a reduction in hospital admissions due to treatment-related side effects, high reported patient satisfaction, and meaningful estimated cost savings. The observed elimination of admissions for GI toxicities and the reduction in febrile neutropenia-related hospitalizations are encouraging and support a potential role for clinical pharmacy services in supportive oncology care. However, given the pre–post design, single-center setting, and absence of a concurrent control group, these findings should be interpreted as hypothesis-generating rather than confirmatory. Larger multicenter controlled studies are warranted to establish the effectiveness, generalizability, and long-term sustainability of this intervention before broader implementation can be recommended.

AUTHORS’ CONTRIBUTION

Conceptualization and supervision: AbdA; Methodology and project administration: AbdA, IAM; Data curation and investigation: All except MajA; Formal analysis and visualization: MajA; Writing – original draft: MajA; Writing – Review and Editing: All except MajA.

Data availability

Available upon request from the corresponding author.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.